<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN" "JATS-journalpublishing1-3.dtd">
<article article-type="research-article" dtd-version="1.3" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="ru"><front><journal-meta><journal-id journal-id-type="publisher-id">clinvest</journal-id><journal-title-group><journal-title xml:lang="ru">Качественная клиническая практика</journal-title><trans-title-group xml:lang="en"><trans-title>Kachestvennaya Klinicheskaya Praktika = Good Clinical Practice</trans-title></trans-title-group></journal-title-group><issn pub-type="ppub">2588-0519</issn><issn pub-type="epub">2618-8473</issn><publisher><publisher-name>ООО «Издательство ОКИ</publisher-name></publisher></journal-meta><article-meta><article-id custom-type="elpub" pub-id-type="custom">clinvest-24</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="ru"><subject>ФАРМАКОЭКОНОМИКА</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="en"><subject>PHARMACOECONOMICS</subject></subj-group></article-categories><title-group><article-title>Сравнительный фармакоэкономический анализ схем лекарственной индукции суперовуляции при проведении экстракорпорального оплодотворения</article-title><trans-title-group xml:lang="en"><trans-title>Comparative pharmacoeconomic analysis schemes dosage of hormonal stimulation during in vitro fertilization</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Крысанов</surname><given-names>И. С.</given-names></name><name name-style="western" xml:lang="en"><surname>Krysanov</surname><given-names>I. S.</given-names></name></name-alternatives><email xlink:type="simple">krysanov-ivan@mail.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Крысанова</surname><given-names>В. С.</given-names></name><name name-style="western" xml:lang="en"><surname>Krysanova</surname><given-names>V. S.</given-names></name></name-alternatives><email xlink:type="simple">noemail@neicon.ru</email><xref ref-type="aff" rid="aff-2"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Толкушин</surname><given-names>А. Г.</given-names></name><name name-style="western" xml:lang="en"><surname>Tolkushin</surname><given-names>A. G.</given-names></name></name-alternatives><email xlink:type="simple">noemail@neicon.ru</email><xref ref-type="aff" rid="aff-3"/></contrib></contrib-group><aff-alternatives id="aff-1"><aff xml:lang="ru"><institution>ГБОУ ВПО Медицинский институт усовершенствования врачей МГУПП</institution><country>Россия</country></aff><aff xml:lang="en"><institution>Postgraduate Medical Institute, Moscow National University of Food Production</institution><country>Russian Federation</country></aff></aff-alternatives><aff-alternatives id="aff-2"><aff xml:lang="ru"><institution>ГБОУ ВПО Первый Московский государственный медицинский университет имени И.М. Сеченова Министерства здравоохранения РФ</institution><country>Россия</country></aff><aff xml:lang="en"><institution>Medical University First Moscow State Medical University named after I.M. Sechenov Ministry of Health</institution><country>Russian Federation</country></aff></aff-alternatives><aff-alternatives id="aff-3"><aff xml:lang="ru"><institution>ООО «МСД Фармасъютикалс»</institution><country>Россия</country></aff><aff xml:lang="en"><institution>LLC «MSD Pharmaceuticals»</institution><country>Russian Federation</country></aff></aff-alternatives><pub-date pub-type="collection"><year>2015</year></pub-date><pub-date pub-type="epub"><day>16</day><month>05</month><year>2018</year></pub-date><volume>0</volume><issue>3</issue><fpage>30</fpage><lpage>33</lpage><permissions><copyright-statement>Copyright &amp;#x00A9; Крысанов И.С., Крысанова В.С., Толкушин А.Г., 2018</copyright-statement><copyright-year>2018</copyright-year><copyright-holder xml:lang="ru">Крысанов И.С., Крысанова В.С., Толкушин А.Г.</copyright-holder><copyright-holder xml:lang="en">Krysanov I.S., Krysanova V.S., Tolkushin A.G.</copyright-holder><license xml:lang="ru" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>Данная работа распространяется под лицензией Creative Commons Attribution 4.0.</license-p></license><license xml:lang="en" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>This work is licensed under a Creative Commons Attribution 4.0 License.</license-p></license></permissions><self-uri xlink:href="https://www.clinvest.ru/jour/article/view/24">https://www.clinvest.ru/jour/article/view/24</self-uri><abstract/><trans-abstract xml:lang="en"><p>Purpose: Definition the scheme of hormonal stimulation, which is the most pharmacoeconomical founded. Methods: Pharmacoeconomic analysis was performed using the cost minimization analysis on the assumption of equal effectiveness compared schemes of hormonal stimulation, which was confirmed in the review of clinical trials and meta-analysis. To estimate the cost of drugs for ovulation induction we used registered VED rates and recommended in the instructions for medical use and the standard of care for infertility using assisted reproductive technologies dosing regimens. Results: The cost of the courses of drugs (1) corifollitropin a + ganirelix (32.9%), corifolhtropin a + ganirelix + follitropin (3 (67.1%) and (2) follitropin a + cetrorelix was 38 108.5 rub. and 47 102 rub., respectively. Cost saving of the budget by using the first scheme was 8 993.5 rub. for one course of in vitro fertilization. Conclusions: The scheme of hormonal stimulation using corifollitropin a is more pharmacoeconomical reasonable.</p></trans-abstract><kwd-group xml:lang="ru"><kwd>корифоллитропин альфа</kwd><kwd>суперовуляция</kwd><kwd>экстракорпоральное оплодотворение</kwd><kwd>вспомогательные репродуктивные технологии</kwd><kwd>анализ минимизации затрат</kwd><kwd>corifolhtropin alfa</kwd><kwd>superovulation</kwd><kwd>assisted reproductive technologies</kwd><kwd>in vitro fertilization</kwd></kwd-group></article-meta></front><back><ref-list><title>References</title><ref id="cit1"><label>1</label><citation-alternatives><mixed-citation xml:lang="ru">Devroey Р, Boostanfar R., Koper N.P., Mannaerts В.М., ljzerman-Boon PC., Fauser В.С. A double-blind, non-inferiority RCT comparing corifollitropin alfa and recombinant FSH during the first seven days of ovarian stimulation using a GnRH antagonist protocol. // Hum Reprod 2009 Dec;24(12):3063-72.</mixed-citation><mixed-citation xml:lang="en">Devroey Р, Boostanfar R., Koper N.P., Mannaerts В.М., ljzerman-Boon PC., Fauser В.С. A double-blind, non-inferiority RCT comparing corifollitropin alfa and recombinant FSH during the first seven days of ovarian stimulation using a GnRH antagonist protocol. // Hum Reprod 2009 Dec;24(12):3063-72.</mixed-citation></citation-alternatives></ref><ref id="cit2"><label>2</label><citation-alternatives><mixed-citation xml:lang="ru">Obruca A. et al. The corifollitropin alfa ENSURE study group Corifollitropin a for ovarian stimulation in IVF: a randomized trial in lower body-weight women. // Reproductive BioMedicine Online (2010).</mixed-citation><mixed-citation xml:lang="en">Obruca A. et al. The corifollitropin alfa ENSURE study group Corifollitropin a for ovarian stimulation in IVF: a randomized trial in lower body-weight women. // Reproductive BioMedicine Online (2010).</mixed-citation></citation-alternatives></ref><ref id="cit3"><label>3</label><citation-alternatives><mixed-citation xml:lang="ru">Pouwer A. W., Farquhar C, Jan AM. Kremer. Long-acting FSH versus daily FSH for women undergoing assisted reproduction. // Intervention Review. Published Online: 13 JUN 2012.</mixed-citation><mixed-citation xml:lang="en">Pouwer A. W., Farquhar C, Jan AM. Kremer. Long-acting FSH versus daily FSH for women undergoing assisted reproduction. // Intervention Review. Published Online: 13 JUN 2012.</mixed-citation></citation-alternatives></ref><ref id="cit4"><label>4</label><citation-alternatives><mixed-citation xml:lang="ru">Государственный реестр предельных отпускных цен производителей на лекарственные препараты, включенные в перечень ЖНВЛП на 06.07.2015г. (http://grls.rosminzdrav.ru/PriceLims.aspx).</mixed-citation><mixed-citation xml:lang="en">Государственный реестр предельных отпускных цен производителей на лекарственные препараты, включенные в перечень ЖНВЛП на 06.07.2015г. (http://grls.rosminzdrav.ru/PriceLims.aspx).</mixed-citation></citation-alternatives></ref><ref id="cit5"><label>5</label><citation-alternatives><mixed-citation xml:lang="ru">Стандарт медицинской помощи при бесплодии с использованием вспомогательных репродуктивных технологий. Утвержден Приказом Минздрава РФ от 30 октября 2012 № 556н.</mixed-citation><mixed-citation xml:lang="en">Стандарт медицинской помощи при бесплодии с использованием вспомогательных репродуктивных технологий. Утвержден Приказом Минздрава РФ от 30 октября 2012 № 556н.</mixed-citation></citation-alternatives></ref><ref id="cit6"><label>6</label><citation-alternatives><mixed-citation xml:lang="ru">Официальная инструкция по применению лекарственного препарата Оргалутран*. Государственный реестр лекарственных средств. Официальный сайт, [электронный ресурс: http://grls.rosminzdrav.ru/]. Дата обращения 6 июля 2015 года.</mixed-citation><mixed-citation xml:lang="en">Официальная инструкция по применению лекарственного препарата Оргалутран*. Государственный реестр лекарственных средств. Официальный сайт, [электронный ресурс: http://grls.rosminzdrav.ru/]. Дата обращения 6 июля 2015 года.</mixed-citation></citation-alternatives></ref><ref id="cit7"><label>7</label><citation-alternatives><mixed-citation xml:lang="ru">Официальная инструкция по применению лекарственного препарата Цетротид*. Государственный реестр лекарственных средств. Официальный сайт, [электронный ресурс: http://grls.rosminzdrav.ru/]. Дата обращения 6 июля 2015 года.</mixed-citation><mixed-citation xml:lang="en">Официальная инструкция по применению лекарственного препарата Цетротид*. Государственный реестр лекарственных средств. Официальный сайт, [электронный ресурс: http://grls.rosminzdrav.ru/]. Дата обращения 6 июля 2015 года.</mixed-citation></citation-alternatives></ref><ref id="cit8"><label>8</label><citation-alternatives><mixed-citation xml:lang="ru">Постановление Правительства РФ от 28.11.2014 г. №1273 «О Программе государственных гарантий бесплатного оказания гражданам медицинской помощи на 2015 год и на плановый период 2016 и 2017 годов».</mixed-citation><mixed-citation xml:lang="en">Постановление Правительства РФ от 28.11.2014 г. №1273 «О Программе государственных гарантий бесплатного оказания гражданам медицинской помощи на 2015 год и на плановый период 2016 и 2017 годов».</mixed-citation></citation-alternatives></ref><ref id="cit9"><label>9</label><citation-alternatives><mixed-citation xml:lang="ru">Williams R.S., Theresa Vensel, Christopher L. Sistrom, Simon Kipersztok, Pregnancy rates in varying age groups after in vitro fertilization: A comparison of follitropin alfa (Gonal F) and follitropin beta (Follistim). // Am J Obstet Gynecol 189:342-7,2003.</mixed-citation><mixed-citation xml:lang="en">Williams R.S., Theresa Vensel, Christopher L. Sistrom, Simon Kipersztok, Pregnancy rates in varying age groups after in vitro fertilization: A comparison of follitropin alfa (Gonal F) and follitropin beta (Follistim). // Am J Obstet Gynecol 189:342-7,2003.</mixed-citation></citation-alternatives></ref><ref id="cit10"><label>10</label><citation-alternatives><mixed-citation xml:lang="ru">Harlin /., Aanesen A, Csemiczky G., Wramsby H„ Fried G. Delivery rates following I VF treatment, using two recombinant FSH preparations for ovarian stimulation. // Human Reproduction Vol.17, No.2 pp. 304-309, 2002.</mixed-citation><mixed-citation xml:lang="en">Harlin /., Aanesen A, Csemiczky G., Wramsby H„ Fried G. Delivery rates following I VF treatment, using two recombinant FSH preparations for ovarian stimulation. // Human Reproduction Vol.17, No.2 pp. 304-309, 2002.</mixed-citation></citation-alternatives></ref></ref-list><fn-group><fn fn-type="conflict"><p>The authors declare that there are no conflicts of interest present.</p></fn></fn-group></back></article>
